Home >> Law >> Food & Beverage >>

Supernus Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published: May-2015 | Format: PDF | Global Markets Direct | Number of pages: 25 | Code: MRS - 19831

Supernus Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Supernus Pharmaceuticals, Inc. - Product Pipeline Review - 2015’, provides an overview of the Supernus Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Supernus Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Supernus Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Supernus Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Supernus Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Supernus Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Supernus Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Supernus Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Supernus Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Supernus Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Supernus Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Supernus Pharmaceuticals, Inc. Snapshot 4
Supernus Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Supernus Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Supernus Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Supernus Pharmaceuticals, Inc. - Pipeline Products Glance 9
Supernus Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Supernus Pharmaceuticals, Inc. - Early Stage Pipeline Products 10
IND/CTA Filed Products/Combination Treatment Modalities 10
Supernus Pharmaceuticals, Inc. - Drug Profiles 11
molindone hydrochloride ER 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
viloxazine hydrochloride 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
SPN-809 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Supernus Pharmaceuticals, Inc. - Pipeline Analysis 14
Supernus Pharmaceuticals, Inc. - Pipeline Products by Target 14
Supernus Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 15
Supernus Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 16
Supernus Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 17
Supernus Pharmaceuticals, Inc. - Recent Pipeline Updates 18
Supernus Pharmaceuticals, Inc. - Dormant Projects 20
Supernus Pharmaceuticals, Inc. - Company Statement 21
Supernus Pharmaceuticals, Inc. - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 24
Disclaimer 25

List of Tables
Supernus Pharmaceuticals, Inc., Key Information 4
Supernus Pharmaceuticals, Inc., Key Facts 4
Supernus Pharmaceuticals, Inc. - Pipeline by Indication, 2015 6
Supernus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 7
Supernus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 8
Supernus Pharmaceuticals, Inc. - Phase II, 2015 9
Supernus Pharmaceuticals, Inc. - IND/CTA Filed, 2015 10
Supernus Pharmaceuticals, Inc. - Pipeline by Target, 2015 14
Supernus Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 15
Supernus Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 16
Supernus Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 17
Supernus Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 18
Supernus Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 20
Supernus Pharmaceuticals, Inc., Subsidiaries 23

List of Figures
Supernus Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 6
Supernus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 7
Supernus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 8
Supernus Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 14
Supernus Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 16
Supernus Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 17

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing